As of 2023, the import volume of blood-grouping reagents to China stood at approximately 390 thousand kilograms. The forecast for 2024 indicates an increase to 405.66 thousand kilograms, with consistent year-on-year growth projected in subsequent years, reaching 474.16 thousand kilograms by 2028. This reflects an average annual growth rate (CAGR) of approximately 3.9% over the five-year forecast period.
Future trends to watch for include:
- Technological advancements in diagnostics potentially influencing import volumes.
- Regulatory changes impacting importation and local production dynamics.
- Shifts in healthcare policy focusing on expanding national inventory reserves for blood-related products.
- Economic factors affecting trade policies and costs.
